BioXcel Completes Phase 3 Trial for Acute Bipolar Agitation
August 1, 2025
BioXcel Therapeutics, a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, announced completion of the last patient last visit (LPLV) in the
